Russian Pharma Sector Analysis (2007)
The report - “Russian Pharma Sector Analysis (2007)” - provides an extensive research and objective analysis on the growing demand of pharmaceuticals in Russia and presents a clear picture of the country’s healthcare and pharmaceutical market.
The Russian pharmaceutical market, in 2006, witnessed one of the strongest growths globally with both the state and commercial segments registering double-digit growth in their sales value. The major impetus for growth was given by the Government’s Drug reimbursement programme, which saw the consumption value of drugs increased by nearly 74% in 2006.
The commercial drugs market, driven by factors such as an ageing population, an increasing demand for imported and expensive medicines, an obligatory health insurance system and increasing disposable incomes, accounts for nearly half of the total pharmaceutical market. Unlike ethical drugs, the nutrition supplements market is dominated by domestic players but the recent restrictions imposed by the State Duma on the promotion of nutritional supplements have retarted the segment’s growth.
The report does a comprehensive analysis of the Russian market, encompassing its demographics, structure of health care sector, size of pharma market, and comparative analysis of the market, among others. Also, a brief overview of the major players operating in the market has been given to present the competitive landscape of the market.
• The DLO programme, that was one of the main drivers fuelling strong growth, may act as a restraint, owing to the government’s recent cost cutting measures.
• The Russian pharmaceutical market witnessed a trend where the drugs sales decreased in volume terms but increased in value terms.
• There was a growth in the demand for imported drugs in Russia.
• Russians are now turning towards expensive drugs with a higher efficacy as compared to the cheaper traditional drugs.
Key Issues Analyzed
• Where does the Russian pharmaceutical market stand in comparison to other key global markets?
• What is the market size of various segments in the Russian pharmaceutical industry?
• What is the proportion of domestic and imported drugs in each segment?
• What are the opportunities that will emerge in future for the market?
Research Methodology Used
The information in the report has been taken from various credible sources like books, newspapers, trade journals, and white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to more than 3000 paid databases.
The analysis methods include ratio analysis, historical trend analysis, linear regression analysis using software tools, judgmental forecasting and cause and effect analysis.
For the purpose of this report, the Russian pharmaceutical market has been considered to consist of the following segments:
• The commercial drugs market;
• The state segment (DLO programme and hospital segment); and
• The Parapharmaceutical segment (Food Supplements and Cosmetics).
The following currency conversion has been taken in the report:
1 Russian Ruble = US$ 0.039, 1 Euro = US$ 1.38
1. Analyst View
2. Global Pharmaceutical Market
2.1 Market Size & Growth
2.2 Geographical Performance
2.3 Leading Therapy Classes
2.4 Leading Pharmaceutical Companies
2.5 Leading Drugs
3. Russian Demographics & Healthcare Profile
3.1.1 Life Expectancy
3.1.2 Age Breakup
3.2 Healthcare Structure
3.2.1 Hospital Beds & Doctors
3.2.2 Healthcare Expenditure
4. Russian Pharmaceutical Market
4.1 Market Overview
4.1.1 Market Size & Growth
4.1.2 Comparative Analysis
4.2 Commercial Drug Market
4.2.2 Imported & Domestic Drugs
4.2.3 RX & OTC Drugs
4.2.4 Sales Structure - By ATC Groups
4.2.5 Leading Pharmaceutical Companies
4.2.6 Leading Drugs
4.2.7 Price Analysis
4.3 State Segment of Pharmaceutical Market
4.3.1 DLO Reimbursement Programme
220.127.116.11 Imported & Domestic Drugs
18.104.22.168 RX & OTC Drugs
22.214.171.124 Sales Structure - By ATC Groups
126.96.36.199 Leading Pharmaceutical Companies
188.8.131.52 Leading Drugs
4.3.2 Hospital Segment
184.108.40.206 Imported & Domestic Drugs
220.127.116.11 Drugs Demand - By Price
18.104.22.168 Leading Pharmaceutical Companies
22.214.171.124 Leading Drugs
4.4 Parapharmaceutical Commercial Market
4.4.1 Nutritional Supplements Market
126.96.36.199 Imported & Domestic Nutritional Supplements
188.8.131.52 Leading Nutritional Supplements
184.108.40.206 Nutritional Supplements Demand - By Price
5. Industry Analysis
5.1.1 Ageing Population
5.1.2 Increasing Volume & Sales of Expensive Drugs
5.1.3 Government Support & Funding
5.1.4 Medical Insurance
5.1.5 Increasing Disposable Income
5.2.1 Cardiovascular Drugs
5.2.2 HIV Drugs
5.2.3 High Insulin Demand
5.2.4 Cancer Drugs
5.2.5 Foreign Players
5.2.7 Clinical Trials Market
5.3.1 Declining Population
5.3.2 DLO Crisis
5.3.3 Ineffective Quality Control of Medicines
5.3.4 Drugs Counterfeiting & Weak IPR Protection
6. Future Outlook (2007- 2011)
7. Key Players
7.3 Roche Group
7.4 Pfizer Inc
List of Tables
Table 2-1: Global - Pharmaceutical Market by Region (in Billion US$), 2006
Table 2-2: Global - Leading Therapy Classes by Sales (in Billion US$), 2006
Table 2-3: Global - Leading Drugs by Sales (in Billion US$), 2006
Table 4-1: Russia - Leading Pharmaceutical Companies by Sales (in Million US$), 2005 & 2006
Table 4-2: Russia - Sales Structure of ATC Groups in Commercial Drugs Market, 2006
Table 4-3: Russia - Leading Pharmaceutical Companies in Commercial Drugs Market by Sales (in Million US$), 2005 & 2006
Table 4-4: Russia - Leading Drugs in Commercial Drugs Market by Sales (in Million US$), 2005 & 2006
Table 4-5: Russia - Sales Structure of ATC Groups under DLO Programme, 2006
Table 4-6: Russia - Leading Pharmaceutical Companies under DLO Programme by Sales (in Million US$), 2005 & 2006
Table 4-7: Russia - Leading Drugs under DLO Programme by Sales (in Million US$), 2005 & 2006
Table 4-8: Russia - Leading Pharmaceutical Companies under Hospital Segment by Sales (in Million US$), 2005 & 2006
Table 4-9: Russia - Leading Drugs under Hospital Segment by Sales (in Million US$), 2005 & 2006
Table 4-10: Russia - Leading Nutritional Supplements in Pharmaceutical Market by Sales (in Million US$), 2005 & 2006
Table 7-1: Sanofi-Aventis - Key Financials (in Million US$), 2004-2006
Table 7-2: Novartis - Key Financials (in Million US$), 2004-2006
Table 7-3: Roche Group - Key Financials (in Million CHF), 2004-2006
Table 7-4: Pfizer Inc - Key Financials (in Million US$), 2004-2006
Table 7-5: AstraZeneca - Key Financials (in Million US$), 2004-2006